Education
About Us
Working with TipRanks
Follow Us
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
RNAZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.14 - $739.20
Previous CloseN/A
Volume52.57K
Average Volume (3M)31.61K
Market Cap
$8.75M
Enterprise Value-$2.30M
Total Cash (Recent Filing)$7.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.20
Next Earnings
Mar 28, 2025EPS Estimate
-105.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-56.61
Shares Outstanding833,683
10 Day Avg. Volume11,257
30 Day Avg. Volume31,606
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.00
Enterprise Value/Ebitda0.09
Forecast
1Y Price Target
$10.00Price Target Upside-8.84% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe safety review committee has approved opening of Cohort 4 in the Phase 1 trial evaluating TTX-MC138 in advanced/metastatic solid tumors, based on favorable safety observed in previous cohorts.
Strategic PartnershipsThe company is engaged in potential pipeline partnerships, indicating strategic growth opportunities following the presentation of initial data.
Bears Say
Financial RisksRisks include, but are not limited to: safety signals emerge with any of the company’s clinical or preclinical programs.
Operating ExpensesIn 4Q24, the company reported operating expenses of $5.1M, which was significantly higher than 3Q24, likely associated with costs related to dose escalation in the Phase 1 trial of TTX-MC138 for treatment of solid tumors.
TransCode Therapeutics News
RNAZ FAQ
What was TransCode Therapeutics’s price range in the past 12 months?
TransCode Therapeutics lowest stock price was $6.14 and its highest was $739.20 in the past 12 months.
What is TransCode Therapeutics’s market cap?
TransCode Therapeutics’s market cap is $8.75M.
When is TransCode Therapeutics’s upcoming earnings report date?
TransCode Therapeutics’s upcoming earnings report date is Mar 28, 2025 which is 163 days ago.
How were TransCode Therapeutics’s earnings last quarter?
Currently, no data Available
Is TransCode Therapeutics overvalued?
According to Wall Street analysts TransCode Therapeutics’s price is currently Overvalued.
Does TransCode Therapeutics pay dividends?
TransCode Therapeutics does not currently pay dividends.
What is TransCode Therapeutics’s EPS estimate?
TransCode Therapeutics’s EPS estimate is -105.93.
How many shares outstanding does TransCode Therapeutics have?
TransCode Therapeutics has 833,683 shares outstanding.
What happened to TransCode Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TransCode Therapeutics?
Currently, no hedge funds are holding shares in RNAZ
TransCode Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (-8.84% Downside)
$10.00 (-8.84% Downside)
Blogger Sentiment
Bullish
RNAZ Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.68%
12-Months-Change
Fundamentals
Return on Equity
-658.62%
Trailing 12-Months
Asset Growth
71.34%
Trailing 12-Months
Company Description
TransCode Therapeutics
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
TransCode Therapeutics (RNAZ) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Palatin Technologies
―
Evogene
―
MetaVia
―
Silexion Therapeutics
―
Lipella Pharmaceuticals, Inc.
―
Ownership Overview
6.76%
Insiders
0.03% Mutual Funds
― Other Institutional Investors
99.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---